|
|
|
|
Дата |
|---|
| 14.04.2026 |
| 13.04.2026 |
| 10.04.2026 |
| 09.04.2026 |
| 08.04.2026 |
| 07.04.2026 |
| 06.04.2026 |
| 02.04.2026 |
| 01.04.2026 |
| 31.03.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
4.41
|
4.73
|
4.04
|
4.00
|
4.685
|
4.64
|
|
|
994 088.13
|
2 800.00
|
|
3.88
|
4.25
|
3.88
|
3.88
|
4.055
|
4.01
|
|
|
728 715.68
|
2 709.00
|
|
3.83
|
3.98
|
3.92
|
3.87
|
4.015405
|
3.94
|
|
|
456 648.82
|
1 678.00
|
|
3.83
|
3.89
|
3.93
|
3.80
|
3.96
|
3.90
|
|
|
516 264.54
|
1 775.00
|
|
3.90
|
3.94
|
4.13
|
3.91
|
4.13
|
3.93
|
|
|
597 742.96
|
2 001.00
|
|
3.98
|
4.20
|
4.12
|
3.94
|
4.12
|
4.04
|
|
|
569 257.80
|
1 747.00
|
|
3.97
|
4.18
|
4.30
|
4.04
|
4.39
|
4.13
|
|
|
941 526.47
|
2 631.00
|
|
3.88
|
4.36
|
3.92
|
3.90
|
4.30
|
4.30
|
|
|
561 378.80
|
2 290.00
|
|
3.88
|
4.13
|
3.80
|
3.77
|
4.13
|
4.09
|
|
|
1 668 204.89
|
4 537.00
|
|
3.57
|
3.85
|
3.75
|
3.49
|
3.8989
|
3.77
|
|
|
1 456 333.31
|
4 462.00
|
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation.
It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Показать все Скрыть